Swamy Sowmya, Koch Christian A, Hannah-Shmouni Fady, Schiffrin Ernesto L, Klubo-Gwiezdzinska Joanna, Gubbi Sriram
Department of Internal Medicine, George Washington University Medical Center, Washington, DC, USA.
Fox Chase Cancer Center, Philadelphia, PA, USA.
J Clin Transl Endocrinol. 2022 Mar;27:100285. doi: 10.1016/j.jcte.2021.100285. Epub 2021 Dec 6.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for coronavirus disease 2019 (COVID-19) has been a major cause of morbidity and mortality globally. Older age, and the presence of certain components of metabolic syndrome, including hypertension have been associated with increased risk for severe disease and death in COVID-19 patients. The role of antihypertensive agents in the pathogenesis of COVID-19 has been extensively studied since the onset of the pandemic. This review discusses the potential pathophysiologic interactions between hypertension and COVID-19 and provides an up-to-date information on the implications of newly emerging SARS-CoV-2 variants, and vaccines on patients with hypertension.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是导致2019冠状病毒病（COVID-19）的病原体，已成为全球发病和死亡的主要原因。年龄较大以及存在某些代谢综合征成分，包括高血压，与COVID-19患者发生重症和死亡的风险增加有关。自大流行开始以来，抗高血压药物在COVID-19发病机制中的作用已得到广泛研究。本综述讨论了高血压与COVID-19之间潜在的病理生理相互作用，并提供了有关新出现的SARS-CoV-2变体和疫苗对高血压患者影响的最新信息。
